Kronos Bio, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 16 rows in 2023. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2023-06-22: Reporting owner Ridloff Elena; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-06-22: Reporting owner DANSEY ROGER D; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-06-22: Reporting owner Stultz Katherine V; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-06-22: Reporting owner Yang Taiyin; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2023-06-22 | Ridloff Elena Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,000 17,000 owned after | $1.48 exercise price | 2023-06-26 | |
| 2023-06-22 | DANSEY ROGER D Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,868 5,868 owned after | $1.48 exercise price | 2023-06-26 | |
| 2023-06-22 | Stultz Katherine V Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,079 7,079 owned after | $1.48 exercise price | 2023-06-26 | |
| 2023-06-22 | Yang Taiyin Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $1.48 exercise price | 2023-06-26 | |
| 2023-06-22 | Blunt Roshawn A. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $1.48 exercise price | 2023-06-26 | |
| 2023-06-22 | De Backer Marianne Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $1.48 exercise price | 2023-06-26 | |
| 2023-06-22 | Kazam Joshua A Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $1.48 exercise price | 2023-06-26 | |
| 2023-06-22 | TANEN DAVID M Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $1.48 exercise price | 2023-06-26 | |
| 2023-06-22 | Belldegrun Arie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $1.48 exercise price | 2023-06-26 | |
| 2023-04-20 | DANSEY ROGER D Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +68,000 68,000 owned after | $1.28 exercise price | 2023-04-24 | |
| 2023-04-10 | Stultz Katherine V Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +68,000 68,000 owned after | $1.29 exercise price | 2023-04-11 | |
| 2023-02-15 | Dinsmore Christopher Officer (Chief Scientific Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +179,824 179,824 owned after | $2.09 exercise price | 2023-02-17 | |
| 2023-02-15 | Kosacz Barbara Officer (COO & General Counsel) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +208,367 208,367 owned after | $2.09 exercise price | 2023-02-17 | |
| 2023-02-15 | DiMartino Jorge Officer (Chief Medical Officer & VP) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +205,513 205,513 owned after | $2.09 exercise price | 2023-02-17 | |
| 2023-02-15 | Al-Wakeel Yasir B. Officer (Chief Financial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +208,367 208,367 owned after | $2.09 exercise price | 2023-02-17 | |
| 2023-02-15 | BISCHOFBERGER NORBERT W Director, Officer (President & CEO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +570,868 570,868 owned after | $2.09 exercise price | 2023-02-17 |